Characterization of in vitro and in vivo metabolism of AG-024322, a novel cyclin-dependent kinase (CDK)
- 1
- 2
- 3
Abstract
Uncontrolled cell proliferation is the hall mark of many cancers, and is typically manifested by a deregulation of the cell-division cycle. CDKs play critical roles in regulating cell cycle, apop- tosis and cell differentiation. AG-024322 is a multitargeted CDK inhibitor that has been shown to induce cancer cell apoptosis and de- monstrate significant antitumor activity in hu-man tumor xenograft models. This compound is under clinical development as an intravenous anticancer agent. AG-024322 exhibited moder-ate to high systemic clearance across preclini-cal species. In vitro metabolism in human liver microsomes and hepatocytes demonstrates that glucuronidation and oxidation represent the major metabolic pathways of AG-024322. The experiments of chemical inhibition and micro-somes containing individual CYP or UGT iso-forms revealed that CYP3A and UGT1A1 appear to predominantly mediate AG-024322 oxidation and glucuronidation, respectively. Formation kinetics of the two pathways in human liver mi-crosomes suggested that the glucuronidation activity of AG-024322 was approximately 3-fold higher as compared to CYP-mediated oxidation, contributing approximately 37% and 13% of the total clearance, respectively, based on the pro-jected human clearance. UGT1A1 is a poly-morphic isoform involved in glucuronidation of bilirubin. It is of concern if glucuronidation via UGT1A1 plays a major role in the elimination of AG-024322 in humans as competitive inhibition of UGT1A1 has been associated with toxicity (Gilbert and Crigler-Najjar syndromes). There-fore, this information was used to influence the clinical study design to only include subjects having constitutive expression of UGT1A1 in the first human study, thereby decreasing the potential risk of toxicity to patients.
- Zhang, C.C., Kephart, S., McAlpine, I., Nonomiya, J., Higgins, J., Arango, M.E., Yan, Z., Knighton, D., Ferre, R.A., Tikhe, J., et al. (2005) AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spec-trum anti-proliferative activity. Proc Amer Assoc Cancer Res, 46, Abstract #4415.
- Morgan, D.O., Fisher, R.P., Espinoza, F.H., Farrell, A., Nourse, J., Chamberlin, H. and Jin, P. (1998) Control of eukaryotic cell cycle progreesion by phosphorylation of cyclin-dependent kinases. Cancer J Sci Am, 4, S77-83.
- Morgan, D.O. (1997) Cyclin-dependent kinases: engines, clocks, and micoprosessors. Annu Rev Cell Biol, 13, 261-291.
- Moriarty, K.J., Koblish, H., Johnson, D.L., Galemmo, J. and Robert, A. (2007) Progress in the development of agents. Top Med Chem, 1, 207-291.
- Zhang, C.C., Troche, G., Yen, Z., Arango, M.E., Higgins, J., Romero, D., Kephart, S., McAlpine, I., Koudriakova, T. and J. Skaptason, et al. (2005) AG-024322 is a multi- targeted CDK inhibitor with potent antitumor activity in vivo. Proc Amer Assoc Cancer Res, 46, Abstract #4413.
- Fisher, M.B., Campanale, K., Ackermann, B.L., Vanden-Branden, M. and Wrighton, S.A. (2000) In vitro glu-curonidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos, 28, 560-566.
- Hamilton, R.A., Garnett, W.R. and Kline, B.J. (1981) Determination of mean valproic acid serum level by as-say of a single pooled sample. Clin Pharmacol Ther, 29, 409-413.
- Venkatakrishnan, K., von Moltke, L.L., Court, M.H., Harmatz, J.S., Crespi, C.L. and Greenblatt, D.J. (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from DNA- expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos, 28, 1493-1504.
- Stormer, E., von Moltke L.L. and Greenblatt, D.J. (2000) Scaling drug biotransformation data from cDNA-ex-pressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapin metabolism. J Pharmacol Exp Ther, 295, 793-801.
- Gomez-Lechon, M.J., Donato, M.T., Castell J.V. and Jover, R. (2004) Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab, 5, 443-462.
- Engtrakul, J.J., Foti, R.S., Strelevitz, T.J. and Fisher, M.B. (2005) Altered AZT (3'-azido-3'-deoxythymidine) glu-curonidation kinetics in liver microsomes as an explana-tion for underprediction of in vivo clearance: Comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos, 33, 1621-1627.